SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.84+3.8%Nov 24 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jayhawk969 who wrote (23004)7/9/1998 9:28:00 PM
From: Henry Niman  Read Replies (1) of 32384
 
JD, I haven't read the patent yet, but LGND was way out in front on small molecules that control gene expression. In 1985 Ron Evans published the first sequence on non-polypeptide hormone receptors. It had homolgy to Erb A (chicken version of a truncated thyroid hormone receptor) and soon there were several sequences which readily define the DNA and hormone binding domain (I made monoclonals to these sequences in 1984). Vitamin A derivatives like tretinoin and isotretinoin had been studied for years and in 1988 Progenx (which later became Ligand) exclusively licensed the Evan's technology which included a co-transfection assay which was designed to identify small molecules that reacted with hormone receptors (transcription factors) that controlled gene expression. The OSIP press release refers to advances in the late 80's which followed the discoveries made by the Evan's technology.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News